Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aprea Therapeutics, Inc. - Common Stock (NQ: APRE )

1.600 +0.100 (+6.67%)
Streaming Delayed Price Updated: 12:18 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,388
Open 1.550
Bid (Size) 1.590 (1)
Ask (Size) 1.600 (3)
Prev. Close 1.500
Today's Range 1.510 - 1.600
52wk Range 1.412 - 5.900
Shares Outstanding 5,481,055
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI Inhibition 
From Aprea Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga

Performance

YTD
-55.18%
-55.18%
1 Month
-29.20%
-29.20%
3 Month
-60.10%
-60.10%
6 Month
-58.97%
-58.97%
1 Year
-70.20%
-70.20%

More News

Read More
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
From Aprea Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
From Aprea Therapeutics
Via GlobeNewswire
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
From Virtual Investor Conferences
Via GlobeNewswire
Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19
From Virtual Investor Conferences
Via GlobeNewswire
UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
From Aprea Therapeutics
Via GlobeNewswire
APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
From Aprea Therapeutics
Via GlobeNewswire
APRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.